Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 0.92 |
| ▸ | CCR3 | P51677 | 20/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14110547 | 0.96 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180270 | 0.96 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180025 | 0.96 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL180112 | 0.95 | HRH1 (0.89) | HRH1CCR3KCNH2 | |
| Hydrochloric Acid SCHEMBL14110672 | 0.95 | HRH1 (0.98) | HRH1CCR3KCNH2 | |
| SCHEMBL180286 | 0.95 | HRH1 (0.98) | HRH1CCR3KCNH2 | |
| SCHEMBL180047 | 0.90 | HRH1 (0.80) | HRH1CCR3KCNH2 | |
| SCHEMBL180375 | 0.90 | HRH1 (0.87) | HRH1CCR3KCNH2 | |
| SCHEMBL180015 | 0.90 | HRH1 (0.85) | HRH1CCR3KCNH2 | |
| SCHEMBL180014 | 0.90 | HRH1 (0.85) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1912941-A1 | NOVEL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007011293-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | HRH1 276/4885CCR3 1/4885KCNH2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.